Table 5.

Gastrin levels from baseline (pg/mL) during treatment and follow-up phases (safety analysis set)

	Keverprazan (n = 180)		Lansoprazole (n = 178)		P Value
	N	Mean (SD)	N	Mean (SD)
Treatment phase
Baseline	180	42.4 (32.6)	177	41.6 (29.7)	0.8053
Week 4	174	236.5 (188.9)	172	100.6 (62.3)	<0.0001
Week 6	24	240.7 (200.2)	26	133.9 (71.4)	0.0139
End of treatment	176	237.6 (187.7)	172	105.1 (67.0)	<0.0001
Follow-up phase
Week 2	116	51.4 (48.0)	50	71.5 (55.6)	0.0197
Week 4	6	56.5 (39.4)	8	98.7 (35.4)	0.0567